VRG Therapeutics Plc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on February 6, 2026 - 11:10 GMT

CREATe Therapeutics Achieves Complete Seizure Prevention in a Severe Model of Focal Epilepsy

Breakthrough Preclinical Result in Epilepsy Treatment LEIDEN, NETHERLANDS, February 6, 2026 /⁨EINPresswire.com⁩/ -- CREATe Therapeutics (CREATe Tx) today announced a major breakthrough demonstrating complete prevention of seizures in a particularly severe …

Distribution channels: Business & Economy, Companies ...

Published on January 9, 2026 - 16:00 GMT

Novamigra Therapeutics Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis asset VRG-145 BUDAPEST, HUNGARY, January 9, 2026 /⁨EINPresswire.com⁩/ -- Novamigra Therapeutics, a spin-out venture of VRG Therapeutics …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on March 6, 2025 - 11:28 GMT

CREATe Therapeutics announces in vivo proof-of-concept results of their small molecule-controlled gene therapy platform

CREATe Therapeutics announces in vivo proof-of-concept results of their small molecule-controlled gene therapy platform, encouraging further development LEIDEN, NETHERLANDS, March 6, 2025 /⁨EINPresswire.com⁩/ -- CREATe Therapeutics (CREATe Tx), a company …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on January 14, 2025 - 13:15 GMT

Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development

Novamigra Tx Announces Successful Pre-IND Meeting with FDA for Migraine Prophylaxis Asset VRG-145, Paving Way for Accelerated Clinical Development BUDAPEST, HUNGARY, January 14, 2025 /⁨EINPresswire.com⁩/ -- Novamigra Tx, a pioneering biopharmaceutical …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on October 18, 2024 - 09:06 GMT

VRG Therapeutics Announces Monthly Dosing for Its Kv1.3 Program for the Treatment of Chronic Inflammatory Diseases

VRG Therapeutics reaches monthly dosing for its lead program targeting Kv1.3 for the treatment of atopic dermatitis and other chronic inflammatory diseases. LEIDEN, NETHERLANDS, October 18, 2024 /⁨EINPresswire.com⁩/ -- VRG Therapeutics (VRG Tx), a …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on April 17, 2024 - 11:00 GMT

VRG Therapeutics Advances VRG-145, a Synergistic Oral Combination for Migraine Prophylaxis, to Final Preclinical Stage

VRG Therapeutics Advances VRG-145, a Novel Synergistic Oral Combination for Migraine Prophylaxis, to Final Preclinical Stage BUDAPEST, HUNGARY, April 17, 2024 /⁨EINPresswire.com⁩/ -- VRG Therapeutics (VRG Tx), a leading biotechnology research and …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on February 20, 2024 - 13:30 GMT

VRG Therapeutics announces validation of its AI-powered drug discovery platform and opens USD 15 million funding round

VRG Therapeutics announces experimental validation of its AI-powered drug discovery platform and opens USD 15 million funding round. BUDAPEST, HUNGARY, February 20, 2024 /⁨EINPresswire.com⁩/ -- VRG Therapeutics (VRG Tx), a biotechnology R&D company …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on January 16, 2024 - 14:00 GMT

VRG Therapeutics announces successful in vivo efficacy results of their CAR-T project targeting glioblastoma

BUDAPEST, HUNGARY, January 16, 2024 /⁨EINPresswire.com⁩/ -- VRG Therapeutics Plc. announces successful in vivo efficacy results of their CAR-T project with patented chlorotoxin analogue targeting glioblastoma, encouraging further development. VRG …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on August 14, 2023 - 10:00 GMT

VRG Therapeutics has secured €5 Million in Series A Funding

BUDAPEST, HUNGARY, August 14, 2023 /⁨EINPresswire.com⁩/ -- VRG Therapeutics (VRG Tx), a pioneering biotechnology research and development company specializing in miniprotein-based pharmaceuticals and cellular & gene therapy (CGT) products, is pleased …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 26, 2023 - 05:00 GMT

VRG Therapeutics demonstrates in vivo efficacy with a selective Kv1.3 inhibitor developed for autoimmune diseases

BUDAPEST, HUNGARY, May 26, 2023 /⁨EINPresswire.com⁩/ -- VRG Therapeutics, a biotechnology R&D company focused on peptide-based pharmaceuticals and cellular & gene therapy (CGT) products has announced that their exceptionally selective Kv1.3 …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on August 17, 2022 - 03:00 GMT

VRG announces major milestone in chlorotoxin targeted CAR T therapy in glioblastoma

Vascular Research Group announced preclinical results of their proprietary CAR T CTXA8 superior to current clinical stage competitor containing natural CTX BUDAPEST, HUNGARY, August 17, 2022 /⁨EINPresswire.com⁩/ -- Vascular Research Group (VRG), a peptide …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...